Study summary

A pill that protects podocytes lowered proteinuria in a third of patients

BI 764198 phase 2 (TRPC6 inhibitor) · 62 people, phase 2 · Published February 2026, The Lancet

35%proteinuria response across doses, vs 7% with placebo

What was tested

BI 764198, a once-daily pill that blocks TRPC6, a calcium channel whose overactivity damages podocytes (the kidney filter cells injured in FSGS), against placebo for 12 weeks.

What they found

What it means

The first evidence that a podocyte-targeted drug works in FSGS; a phase 3 trial has started.

Lancet, via PubMed ↗ ← Back to the outlook
Last reviewed 2026-11-16 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.